A family of mixed-ligand oxovanadium(V) complexes incorporating tridentate ONO donor hydrazone ligands derived from acetylhydrazide and 2-hydroxybenzaldehyde/2-hydroxyacetophenone

A Study on the Electronic Effect of para-substituents in the Aryloxy Ring of the Hydrazone Ligands on the Vanadium Centre in the mixed-ligand [VIVO(ONO)(NN)] families

The hyperfine coupling constant (Aıı) and the redox potential (E½) values of vanadium(IV) in its mixed-ligand hydrazone complexes [VIVO(L)(bipy)], 1–4 and [VIVO(L)(phen)], 5–8, [which have been synthesised from the reaction of VIVO(acac)2 with the hydrazone ligand H2L in the presence of equimolar amount of 2,2′-bipyridine (bipy) or 1,10-phenanthroline (phen) in methanol], exhibit a linear relationship with the Hammett constant (σ) of the para-substituents in the aryloxy ring of the hydrazone ligands.

Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone

The present paper deals with in silico evaluation of 32 virtually designed transition metal complexes of 2-butanone thiosemicarbazone and N,S,O containing donor hetero-ligands namely py, bpy, furan, thiophene, 2-picoline, 1,10-phenanthroline, piperazine and liquid ammonia. The complexes were designed with a view to assess their potential anticancer, antioxidant and antibacterial activity. The absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of the chosen ligands were calculated by admetSAR software. Metabolic sites of different ligands likely to undergo metabolism were predicted using Metaprint 2D. The proposed complexes were also evaluated for their drug-like quality based on Lipinski's, Veber, Ghose and leadlikeness filters. Druglikeness and toxicity potential were predicted by OSIRIS property explorer. The pharmacokinetic properties and bioactivity scores were calculated by Molinspiration tool. Bioactivity scores of the complexes were predicted for drug targets including enzymes, nuclear receptors, kinase inhibitors, G-protein coupled receptor ligands and ion channel modulators. Molecular docking of selected Fe(II) mixed-ligand complexes was performed using AutoDock version 4.2.6 and i-GEMDOCK version 2.1 with two target proteins namely Ribonucleotide reductase (RR) and Topoisomerase II (Topo II). The results were compared with three standard reference drugs viz. Doxorubicin HCl, Letrozole (anticancer) and Tetracycline (antibiotic). Multivariate data obtained were analyzed using principal component analysis (PCA) for visualization and projection as scatter and 3D plots. Positive results obtained for hetero-ligands using admetSAR version 1.0 indicated good absorption and transport kinetics of the hetero-ligand complexes through the human intestine and blood-brain barrier. The hetero-ligands were predicted to have no associated mutagenic effect(s) also. However, none of the hetero-ligands was predicted to be Caco-2 (human colon cancer cell line) permeable. Most of the hetero-ligands and the parent ligand (2-butanone thiosemicarbazone) were predicted to undergo Phase-I metabolism prior to excretion using MetaPrint2D software. Pharmacokinetic evaluation of the proposed complexes revealed that all complexes displayed drug-like character and were predicted to have no apparent toxic side-effects. All the proposed complexes showed moderate to good biological activity scores (-5.0 to 0.0). Mixed complexes with bpy, 2-picoline and 1,10-phenanthroline showed significant bioactivity scores (as enzyme inhibitors) in the range 0.02-0.13. Likewise, good docking scores were obtained for Fe (II) complexes with the same ligands. [FeL(2-pic)₂] displayed the lowest binding energy (-6.47 kcal/mol) with respect to Topo II followed by [FeL(py)₂] (-6.14 kcal/mol) as calculated by AutoDock version 4.2.6. With respect to binding with RR, [FeL(2--pic)₂] again displayed the lowest binding energy (-7.21 kcal/mol) followed by [FeL(py)₂] (-5.96 kcal/mol). On the basis of docking predictions and various other computational evaluations, four mixed-ligand complexes of Fe in +2 oxidation state with py, bpy, 2--picoline and 1,10-phenanthroline were synthesized with 2-butanone thiosemicarbazone. All the synthesized Fe complexes were characterized using various spectroscopic techniques and tested for their potential anticancer activity in vitro against human breast carcinoma cell line MDA-MB 231 and human lung carcinoma cell line A549 cell line using MTT assay. [FeL(2-pic)₂], [FeL(bpy)], and [FeL(py)₂] were found to exhibit significant antiproliferative activity with IC₅₀ values in the range of 80-100 μM against breast and lung cancer cells. The synthesized Fe complexes also displayed mild antioxidant activities. The synthesized and studied Fe complexes have the potential for development into future anticancer agents if analyzed and modified further for improvement of their ADMET, solubility and permeability criteria set for potential drug-candidates.

Supramolecular structure, mixed ligands and substituents effect on the spectral studies of oxovanadium(IV) complexes of bioinorganic and medicinal relevance

An interesting series of heterocyclic mixed ligand of oxovanadium(IV) complexes have been synthesized by the reaction of vanadium(IV) sulfate with rhodanine azo (HL(n)) in the presence of β-diketon (LH). The elemental analysis, magnetic moments, spectral (UV-Vis, IR, (1)HNMR and ESR) with thermal studies were used to characterize the isolated complexes. The IR showed that the ligands (HL(n) and LH) act as a monobasic bidentate through the (NN), oxygen keto moiety and oxygen atom of the two enolate groups thereby forming a six-membered. The molar conductivities show that all the complexes are non-electrolytes. The ESR spectra indicate that the free electron is in d(xy) orbital. The calculated bonding parameter indicates that in-plane σ-bonding is more covalent than in-plane π-bonding. The coordination geometry around oxovanadium(IV) in all complexes is a hex-coordinated trans octahedral, with one bidentate ligand (L(n)), and one bidentate ligand (L). Electronic and magnetic data proposed the octahedral structure for all complexes under investigation. ESR spectra of VO(2+) reveal data that confirmed the proposed structure. The value of covalency factor (β(1)(∗))(2) and orbital reduction factor K accounts for the covalent nature of the complexes. All electronic transitions were assigned. The Hammett's constant is also discussed.

Microwave assisted synthesis and characterization of unsymmetrical tetradentate Schiff base complexes of VO(IV) and MoO(V)

Microwave synthesis, is green chemical method, simple, sensitive, reducing solvent amount and reaction time. The attempt was made to synthesize the unsymmetrical tetradentate N(2)O(2) ligands and their VO(IV) and MoO(V) unsymmetrical tetradentate Schiff base complexes by classical and microwave techniques using domestic microwave oven. The resulting unsymmetrical Schiff base ligands L(1)-L(3) characterized by different spectral methods. Their complexes with oxocations of VO(IV) and MoO(V) have been synthesized and characterized by elemental analyses, conductometric measurements, infrared and electronic absorption, (1)H NMR spectra, mass spectrometry, ESR spectra, magnetic susceptibility measurement and thermal study. The study suggests that the oxo metal ion is bonded to the ligand through the oxygen and imino nitrogen and the geometry around metal ion is distorted octahedral.

Ligating behaviour of Schiff base ligands derived from heterocyclic beta-diketone and ethanol or propanol amine with oxovanadium (IV) metal ion

Synthesis and evaluation of six new oxovanadium (IV) complexes, formed by the interaction of vanadyl sulphate pentahydrate and the Schiff base, viz.; (HL(1))-(HL(3)) and (HL(4))-(HL(6)) such as 5-hydroxy-3-methyl-1(2-chloro)phenyl-1H-pyrazolone-4-carbaldehyde (I), 5-hydroxy-3-methyl-1(3-chloro)phenyl-1H-pyrazolone-4-carbaldehyde (II) and 5-hydroxy-3-methyl-1(3-sulphoamido)phenyl-1H-pyrazolone-4-carbaldehyde (III) with ethanol amine and propanol amine, respectively, in aqueous ethanol medium. The ligands and their Schiff base ligands have been characterized by elemental analyses, IR and (1)H NMR. The resulting complexes have been characterized by elemental analyses, IR, (1)H NMR, mass, electronic, electron spin resonance spectra, magnetic susceptibility measurement, molar conductance and thermal studies. The IR spectral data suggest that the ligand behaves as a dibasic bidentate with ON donor sequence towards metal ion. The molar conductivity data show them to be non-electrolytes. From the electronic, magnetic and ESR spectral data suggest that all the oxovanadium (IV) complexes have distorted octahedral geometry.